Funding
← Back to your selection

Soleus Capital

Activity from announced rounds

Activity in this selectionSeries C+
Rounds participated in
2
Confirmed lead rounds
—
2 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$371M
2 disclosed · full round size, not this investor’s share

By stage

Series C+2

By primary sector

Biotech2

By country

United States2

Rounds

2 in this selection
Abcuro

Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease.

$66MSeries D
Role not disclosed
Parabilis Medicines

Develops medicines targeting historically undruggable protein targets in cancer

$305MSeries F
Role not disclosed